Selected stock price target news of the day - March 31st, 2025

By: Matthew Otto

Humacyte Reports Q4 2024 Results: FDA Approval, Clinical Developments, and Improved EPS

Humacyte announced its fourth-quarter and full-year 2024 financial results, including the U.S. Food and Drug Administration (FDA) approval and commercial launch of Symvess™ for extremity vascular trauma. It reported that 34 hospitals have initiated the Value Analysis Committee (VAC) approval process, with three hospitals approving purchases.

Extremity vascular trauma affects approximately 200,000 people in the U.S. annually, with many cases leading to amputation. Humacyte also plans to file an Investigational New Drug (IND) application in 2025 to support clinical trials for its small-diameter ATEV™ in coronary artery bypass grafting (CABG), which affects over 400,000 patients in the U.S. annually. Additionally, results from a Phase 3 trial of ATEV for dialysis access, involving 350 patients, were presented at the American Society of Nephrology’s Kidney Week 2024, potentially impacting the 500,000 U.S. patients who require dialysis access each year.

Financially, Humacyte reported a Q4 2024 earnings per share (EPS) of ($0.16), exceeding analyst estimates of ($0.25) by $0.09. Posted a net loss of $20.9 million for Q4 2024, compared to $39.2 million in Q3 2024 and $25.1 million in Q4 2023, largely due to a non-cash remeasurement of contingent earnout liabilities. Research and development expenses were $20.7 million for Q4 2024 and $88.6 million for the year, an increase from $76.6 million in 2023, reflecting manufacturing and personnel costs. General and administrative expenses were $7.4 million for Q4 2024 and $25.8 million for the year, compared to $23.5 million in 2023.

Analysts Maintain Buy Ratings with Price Targets Increase

D. Boral Capital analyst Jason Kolbert maintained a Buy rating and a $25 price target.
Benchmark analyst Bruce D. Jackson reiterated a Buy rating and a $17 price target.

Which Analyst has the best track record to show on HUMA?

Analyst Joshua Jennings (TD COWEN) currently has the highest performing score on HUMA with 2/5 (40%) price target fulfillment ratio. His price targets carry an average of $4.97 (98.81%) potential upside. Humacyte stock price reaches these price targets on average within 270 days.

Microsoft-Backed OpenAI Faces Year-End Deadline for $40 Billion Funding

Microsoft-backed OpenAI must transition to a for-profit company by December 31 to secure the full $40 billion funding round led by SoftBank, according to a person familiar with the matter. If OpenAI does not complete its restructuring by the deadline, SoftBank may reduce the investment to $20 billion.

The Wall Street Journal first reported the news, highlighting that OpenAI originally had a two-year timeline to transition after its last funding round. Microsoft has invested more than $13 billion in OpenAI to date and holds a 49% stake in the for-profit subsidiary of the AI research firm.

The potential $40 billion funding would be one of the largest private investments in AI, pushing OpenAI’s valuation beyond its current estimate of $80 billion. Its restructuring decision comes as the AI sector sees rising investments, with Anthropic securing $2.75 billion from Amazon and Google pledging up to $2 billion to DeepMind’s efforts.

OpenAI’s most recent financing round, completed earlier this year, raised $300 million from investors including Sequoia Capital and Andreessen Horowitz. The outcome of this transition will determine whether OpenAI secures the full funding amount or faces a scaled-down investment.

Analyst Lowers Price Target 500 Amid OpenAI Funding Uncertainty

Jefferies analyst Brent Thill maintained with a Buy and lowered the price target from $550 to $500.

Which Analyst has the best track record to show on MSFT?

Analyst Mark Murphy (JPMORGAN) currently has the highest performing score on MSFT with 26/28 (92.86%) price target fulfillment ratio. His price targets carry an average of $60.27 (14.89%) potential upside. Microsoft stock price reaches these price targets on average within 117 days.

ADC Therapeutics Reports Q4 and Full-Year 2024 Financial Results and Clinical Progress

ADC Therapeutics reported key clinical and financial updates for the fourth quarter and full year ended December 31, 2024. Highlighted data from its LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab, which demonstrated a 94% best overall response rate (ORR) and a 72% complete response rate (CRR) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients.

The trial enrolled 29 patients with relapsed or refractory non-Hodgkin lymphoma (NHL), with 18 DLBCL patients evaluable for efficacy. Enrollment is expected to expand to 40 patients in 2025, with additional data anticipated in the second half of the year. ADC Therapeutics also completed enrollment of 330 patients in the LOTIS-5 Phase 3 confirmatory trial evaluating ZYNLONTA with rituximab in second-line or later DLBCL.

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, affecting approximately 150,000 people globally each year, with an estimated 28,000 new cases diagnosed annually in the U.S. alone. Around 40% of patients with DLBCL experience relapse or become refractory to initial treatment.

Financially, ADC Therapeutics reported Q4 earnings per share (EPS) of ($0.25), exceeding analyst estimates of ($0.43) by $0.18. Revenue for the quarter was $16.91 million, below the consensus estimate of $18.85 million. Full-year net product revenues reached $69.3 million, compared to $69.1 million in 2023. R&D expenses declined to $27.1 million in Q4 and $109.6 million for the full year.

Selling and marketing (S&M) expenses fell to $11.3 million in Q4 and $44.0 million for the year, while general and administrative (G&A) expenses decreased to $9.6 million and $41.9 million, respectively. Net loss improved to $30.7 million ($0.29 per share) in Q4, compared to $85.0 million ($1.03 per share) in Q4 2023. Full-year net loss also decreased to $157.8 million ($1.62 per share) from $240.1 million ($2.94 per share) in 2023. Adjusted net loss for 2024 was $111.4 million ($1.15 per share), down from $185.7 million ($2.27 per share) in 2023.

Analysts Revise Price Targets While Maintaining Ratings

Guggenheim analyst Michael Schmidt maintained a Buy rating; however, lowered the price target from $10 to $7.
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating and a $8 price target.

Which Analyst has the best track record to show on ADCT?

Analyst Robert Burns (HC WAINWRIGHT) currently has the highest performing score on ADCT with 1/11 (9.09%) price target fulfillment ratio. His price targets carry an average of $6.06 (312.37%) potential upside. ADC Therapeutics stock price reaches these price targets on average within 70 days.